-
Je něco špatně v tomto záznamu ?
Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers
R. Novobilský, P. Bartova, K. Lichá, M. Bar, D. Stejskal, P. Kusnierova
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2008
Free Medical Journals
od 2007
PubMed Central
od 2007
Europe PubMed Central
od 2007
ProQuest Central
od 2023-01-01
Open Access Digital Library
od 2007-01-01
Open Access Digital Library
od 2008-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2008
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Serum neurofilament light chain (S NfL) is a non-specific marker of neuronal damage, including Alzheimer's disease (AD). We aimed to verify the reference interval (RI) of serum NfL using a highly sensitive ELISA, and to estimate the optimal cut-off value for neuronal damage. Our second objective was to compare NfL in cerebrospinal fluid (CSF) and serum (S) with the routine neurodegeneration biomarkers used in AD, and to assess their concentrations relative to the degree of cognitive deficit. METHODS: Samples from 124 healthy volunteers were used to estimate the S NfL RI. For the comparison study, we used CSF and S samples from 112 patients with cognitive disorders. Cognitive functions were assessed using the mini-mental state examination. ELISA assays were used to determine the CSF and S NfL levels, CSF β-amyloid peptide42 (Aβ42), CSF β-amyloid peptide40 (Aβ40), CSF total tau protein (tTau), CSF phosphorylated tau protein (pTau), and CSF alpha-synuclein (αS). RESULTS: The estimated RI of S NfL were 2.25-9.19 ng.L-1. The cut-off value of S NfL for assessing the degree of neuronal impairment was 10.5 ng.L-1. We found a moderate statistically significant correlation between S NfL and CSF Aβ42 in the group with movement disorders, without dementia (rs = 0.631; p = 0.016); between S NfL and CSF Aβ40 in the group with movement disorder plus dementia (rs = -0.750; p = 0.052); between S NfL and CSF tTau in the control group (rs = 0.689; p = 0.009); and between S NfL and CSF pTau in the control group (rs = 0.749; p = 0.003). The non-parametric Kruskal-Wallis test revealed statistically significant differences between S NfL, CSF NfL, CSF Aβ42, CSF tTau, and CSF pTau and diagnosis within groups. The highest kappa coefficients were found between the concentrations of S NfL and CSF NfL (κ = 0.480) and between CSF NfL and CSF tTau (κ = 0.351). CONCLUSION: Our results suggested that NfL and tTau in CSF of patients with cognitive decline could be replaced by the less-invasive determination of S NfL using a highly sensitive ELISA method. S NfL reflected the severity of cognitive deficits assessed by mini-mental state examination (MMSE). However, S NfL is not specific to AD and does not appear to be a suitable biomarker for early diagnosis of AD.
Department of Clinical Neurosciences University of Ostrava Ostrava Czechia
Department of Neurology University Hospital Ostrava Ostrava Czechia
Institute of Laboratory Medicine University of Ostrava Ostrava Czechia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006165
- 003
- CZ-PrNML
- 005
- 20240412130905.0
- 007
- ta
- 008
- 240405e20231214sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fnhum.2023.1284416 $2 doi
- 035 __
- $a (PubMed)38164192
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Novobilský, Richard $u Department of Neurology, University Hospital Ostrava, Ostrava, Czechia $u Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czechia
- 245 10
- $a Serum neurofilament light chain levels in patients with cognitive deficits and movement disorders: comparison of cerebrospinal and serum neurofilament light chain levels with other biomarkers / $c R. Novobilský, P. Bartova, K. Lichá, M. Bar, D. Stejskal, P. Kusnierova
- 520 9_
- $a BACKGROUND: Serum neurofilament light chain (S NfL) is a non-specific marker of neuronal damage, including Alzheimer's disease (AD). We aimed to verify the reference interval (RI) of serum NfL using a highly sensitive ELISA, and to estimate the optimal cut-off value for neuronal damage. Our second objective was to compare NfL in cerebrospinal fluid (CSF) and serum (S) with the routine neurodegeneration biomarkers used in AD, and to assess their concentrations relative to the degree of cognitive deficit. METHODS: Samples from 124 healthy volunteers were used to estimate the S NfL RI. For the comparison study, we used CSF and S samples from 112 patients with cognitive disorders. Cognitive functions were assessed using the mini-mental state examination. ELISA assays were used to determine the CSF and S NfL levels, CSF β-amyloid peptide42 (Aβ42), CSF β-amyloid peptide40 (Aβ40), CSF total tau protein (tTau), CSF phosphorylated tau protein (pTau), and CSF alpha-synuclein (αS). RESULTS: The estimated RI of S NfL were 2.25-9.19 ng.L-1. The cut-off value of S NfL for assessing the degree of neuronal impairment was 10.5 ng.L-1. We found a moderate statistically significant correlation between S NfL and CSF Aβ42 in the group with movement disorders, without dementia (rs = 0.631; p = 0.016); between S NfL and CSF Aβ40 in the group with movement disorder plus dementia (rs = -0.750; p = 0.052); between S NfL and CSF tTau in the control group (rs = 0.689; p = 0.009); and between S NfL and CSF pTau in the control group (rs = 0.749; p = 0.003). The non-parametric Kruskal-Wallis test revealed statistically significant differences between S NfL, CSF NfL, CSF Aβ42, CSF tTau, and CSF pTau and diagnosis within groups. The highest kappa coefficients were found between the concentrations of S NfL and CSF NfL (κ = 0.480) and between CSF NfL and CSF tTau (κ = 0.351). CONCLUSION: Our results suggested that NfL and tTau in CSF of patients with cognitive decline could be replaced by the less-invasive determination of S NfL using a highly sensitive ELISA method. S NfL reflected the severity of cognitive deficits assessed by mini-mental state examination (MMSE). However, S NfL is not specific to AD and does not appear to be a suitable biomarker for early diagnosis of AD.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bartova, Petra $u Department of Neurology, University Hospital Ostrava, Ostrava, Czechia $u Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czechia
- 700 1_
- $a Lichá, Karin $u Department of Clinical Biochemistry, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czechia
- 700 1_
- $a Bar, Michal $u Department of Neurology, University Hospital Ostrava, Ostrava, Czechia $u Department of Clinical Neurosciences, University of Ostrava, Ostrava, Czechia
- 700 1_
- $a Stejskal, David $u Department of Clinical Biochemistry, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czechia $u Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czechia
- 700 1_
- $a Kusnierova, Pavlína $u Department of Clinical Biochemistry, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czechia $u Institute of Laboratory Medicine, University of Ostrava, Ostrava, Czechia
- 773 0_
- $w MED00174547 $t Frontiers in human neuroscience $x 1662-5161 $g Roč. 17 (20231214), s. 1284416
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38164192 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130858 $b ABA008
- 999 __
- $a ok $b bmc $g 2076150 $s 1215927
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 17 $c - $d 1284416 $e 20231214 $i 1662-5161 $m Frontiers in human neuroscience $n Front. hum. neurosci. $x MED00174547
- LZP __
- $a Pubmed-20240405